West Pharmaceutical Services Inc   (WST)
Other Ticker:  
   Industry ../Industry/Industry_Performance.php?ind=804"> Medical Equipment & Supplies
   Sector  Healthcare
Price: $331.9600 $2.24 0.679%
Day's High: $333.92 Week Perf: 1.03 %
Day's Low: $ 328.55 30 Day Perf: 3.81 %
Volume (M): 425 52 Wk High: $ 424.00
Volume (M$): $ 141,083 52 Wk Avg: $291.86
Open: $330.03 52 Wk Low: $206.19

 Market Capitalization (Millions $) 25,161
 Shares Outstanding (Millions) 76
 Employees 8,200
 Revenues (TTM) (Millions $) 2,887
 Net Income (TTM) (Millions $) 586
 Cash Flow (TTM) (Millions $) 132
 Capital Exp. (TTM) (Millions $) 285

West Pharmaceutical Services Inc

West Pharmaceutical Services, Inc. and its majority-owned subsidiaries is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. Our products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services. Our customers include the leading biologic, generic, pharmaceutical, diagnostic, and medical device companies in the world. The Company was incorporated under the laws of the Commonwealth of Pennsylvania on July 27, 1923.

In 2015, our business operations consisted of two reportable segments, the Pharmaceutical Packaging Systems segment (“Packaging Systems”) and the Pharmaceutical Delivery Systems segment (“Delivery Systems”). Beginning in 2016, we changed our organization and reporting structure for our next phase of growth and development, which resulted in a change to Proprietary Products and Contract-Manufactured Products as our reportable segments.

Proprietary Products Segment

Our Proprietary Products reportable segment, which is a combination of the previous Packaging Systems segment and the proprietary products portion of the previous Delivery Systems segment, develops commercial, operational, and innovation strategies across our global network, with specific emphasis on product offerings to biologic, generic, and pharmaceutical drug customers.

Proprietary Products offers proprietary packaging, containment and drug delivery products. The packaging products include stoppers and seals for injectable packaging systems, which are designed to help ensure drug compatibility and stability, while also supporting operational efficiency. Proprietary Products also offers syringe and cartridge components, including custom solutions for the specific needs of injectable drug applications, as well as administration systems that can enhance the safe delivery of drugs through advanced reconstitution, mixing and transfer technologies.

In 2016, we announced the availability of the 1-3mL NovaPure® plunger, an innovative, high-quality component for pre-filled delivery systems, designed to reduce particulates, ensure consistency of delivery and fit the changing needs of higher-volume injectable drug delivery systems. This new offering adds to our current portfolio of NovaPure products, which includes the 1mL long NovaPure plunger and 13mm and 20mm NovaPure lyo and serum stoppers. Our NovaPure plungers are designed and manufactured using scientific, risk-mitigating Quality by Design principles to ensure dimensional control and consistency, sub-visible and visible particulate control, and low parts per million defect attributes.

We also offer drug containment solutions, including CZ vials, syringes and cartridges, which can provide a high-quality solution to glass incompatibility issues and can stand up to cold storage environments, while reducing the risk of breakage that exists with glass. It is an integrated life-cycle solution that is designed to maintain drug safety, purity and efficacy.

In addition, we offer a variety of self-injection systems, which are innovative, patient-centric technologies that are easy to use and can be combined with connected health technologies that have the potential to increase adherence.

The development of our SmartDose® technology platform continues to gain momentum in the marketplace, as the U.S. Food and Drug Administration (“FDA”) approved the first combination product that incorporates our SmartDose technology for use in the U.S. in July 2016, and several other active development programs are in place. This technology platform is designed for controlled, subcutaneous delivery of high volume and high viscosity drugs, and the device incorporates prefillable CZ cartridges. The technology platform is fully programmable, has a single push-button operation and a hidden needle for safety.

Our Contract-Manufactured Products reportable segment, which consists of the contract manufacturing portion of the previous Delivery Systems segment, serves as a fully integrated business focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers.

Contract-Manufactured Products includes a variety of custom contract-manufacturing and assembly solutions, which use such technologies as multi-component molding, in-mold labeling, ultrasonic welding and clean room molding and device assembly. We manufacture customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.

   Company Address: 530 Herman O. West Drive Exton 19341 PA
   Company Phone Number: 594-2900   Stock Exchange / Ticker: NYSE WST
   WST is expected to report next financial results on April 27, 2023.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Enzo Biochem Inc

Extremely pressing reporting season for Enzo Biochem Inc during the financial time-frame ending January 31 2023

Enzo Biochem Inc disclosed disastrous second quarter of 2022 financial report, where Sales faded by -52.012 % to $16.34 millions and a shortfall per share has expanded to $-0.23, from the corresponding reporting season a year ago.

Chemomab Therapeutics Ltd

Working outlays were on the rise at the CMMB in the fiscal interval closing December 31 2022

As the October to December 31 2022 reporting season continues, many entities have announced the earnings. In the thick of it, have been many companies in the Major Pharmaceutical Preparations industry. And today, CMMB reported operating loss of $-8.642 millions, for the fourth quarter of 2022 earnings season.

Eterna Therapeutics Inc

As one of many corporations, the Eterna Therapeutics Inc published also the fourth quarter of 2022 numbers

The stockholders did not expect some adjustments at the business during the the October to December 31 2022 reporting cycle at the ERNA. But, investors observe the company's operating shortfall that has been at $-4.737 millions, in the same period.

Camtek Ltd

the Scientific & Technical Instruments company delivered astonishing most recent fiscal period Sales and bottom-line growth , where Sales grew by 19.005 % to $320.91 millions when compared with the prior year period, bottom-line were up by 23.88 % at $1.66 per share.

Exagen Inc

Shortfall Despite of Sales advance at in the October to December 31 2022 time-frame

For the October to December 31 2022 time-frame company increased a deficit per share of $-0.83 per share compare to $-0.41 a year ago and surged deficit from $-0.47 per share from the preceding reporting season.

Sales grew softly by 1.166 % to $12.84 millions from $12.69 millions in the similar reporting season a year ago and sequentially Sales deteriorated by -12.828 % from $14.73 millions.


West Pharmaceutical Services Inc 's Segments
• View Complete Report


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

CPIX's Profile

Stock Price

CPIX's Financials

Business Description


Charts & Quotes

CPIX's News


CPIX's Competitors

Customers & Markets

Economic Indicators

CPIX's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries




At a Glance








About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071